Complete response to bicalutamide withdrawal prolonged for almost 2 years in patients with metastatic prostate cancer

Hiroshi Hongo; Takeo Kosaka; Mototsugu Oya

doi:10.1016/j.eucr.2014.06.002

Complete response to bicalutamide withdrawal prolonged for almost 2 years in patients with metastatic prostate cancer

Hiroshi Hongo, Takeo Kosaka, Mototsugu Oya

Department of Urology

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

This is the first case report describing a complete response to bicalutamide withdrawal that lasted for almost 2years in a patient with metastatic prostate cancer. An 80-year-old man who had prostate-specific antigen (PSA) level elevation (168.1ng/mL) visited our hospital in February 2010. Bone scintigraphy showed pelvic metastases. We started hormonal therapy with leuprorelin and bicalutamide. The PSA concentration decreased to <0.1ng/mL but started increasing again and reached 1.64ng/mL in October 2012, at which time bicalutamide administration was discontinued. The PSA concentration decreased again and has remained below the limit of sensitivity for almost 2years.

Original language	English
Pages (from-to)	150-151
Number of pages	2
Journal	Urology Case Reports
Volume	2
Issue number	5
DOIs	https://doi.org/10.1016/j.eucr.2014.06.002
Publication status	Published - 2014 Sept

Keywords

Antiandrogen withdrawal syndrome
Bicalutamide
Prostate cancer

ASJC Scopus subject areas

Urology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.eucr.2014.06.002

Cite this

@article{063ce720bf4d449eb62f457615c4df11,

title = "Complete response to bicalutamide withdrawal prolonged for almost 2 years in patients with metastatic prostate cancer",

abstract = "This is the first case report describing a complete response to bicalutamide withdrawal that lasted for almost 2years in a patient with metastatic prostate cancer. An 80-year-old man who had prostate-specific antigen (PSA) level elevation (168.1ng/mL) visited our hospital in February 2010. Bone scintigraphy showed pelvic metastases. We started hormonal therapy with leuprorelin and bicalutamide. The PSA concentration decreased to <0.1ng/mL but started increasing again and reached 1.64ng/mL in October 2012, at which time bicalutamide administration was discontinued. The PSA concentration decreased again and has remained below the limit of sensitivity for almost 2years.",

keywords = "Antiandrogen withdrawal syndrome, Bicalutamide, Prostate cancer",

author = "Hiroshi Hongo and Takeo Kosaka and Mototsugu Oya",

year = "2014",

month = sep,

doi = "10.1016/j.eucr.2014.06.002",

language = "English",

volume = "2",

pages = "150--151",

journal = "Urology Case Reports",

issn = "2214-4420",

publisher = "Elsevier Saunders",

number = "5",

}

TY - JOUR

T1 - Complete response to bicalutamide withdrawal prolonged for almost 2 years in patients with metastatic prostate cancer

AU - Hongo, Hiroshi

AU - Kosaka, Takeo

AU - Oya, Mototsugu

PY - 2014/9

Y1 - 2014/9

N2 - This is the first case report describing a complete response to bicalutamide withdrawal that lasted for almost 2years in a patient with metastatic prostate cancer. An 80-year-old man who had prostate-specific antigen (PSA) level elevation (168.1ng/mL) visited our hospital in February 2010. Bone scintigraphy showed pelvic metastases. We started hormonal therapy with leuprorelin and bicalutamide. The PSA concentration decreased to <0.1ng/mL but started increasing again and reached 1.64ng/mL in October 2012, at which time bicalutamide administration was discontinued. The PSA concentration decreased again and has remained below the limit of sensitivity for almost 2years.

AB - This is the first case report describing a complete response to bicalutamide withdrawal that lasted for almost 2years in a patient with metastatic prostate cancer. An 80-year-old man who had prostate-specific antigen (PSA) level elevation (168.1ng/mL) visited our hospital in February 2010. Bone scintigraphy showed pelvic metastases. We started hormonal therapy with leuprorelin and bicalutamide. The PSA concentration decreased to <0.1ng/mL but started increasing again and reached 1.64ng/mL in October 2012, at which time bicalutamide administration was discontinued. The PSA concentration decreased again and has remained below the limit of sensitivity for almost 2years.

KW - Antiandrogen withdrawal syndrome

KW - Bicalutamide

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84906502928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906502928&partnerID=8YFLogxK

U2 - 10.1016/j.eucr.2014.06.002

DO - 10.1016/j.eucr.2014.06.002

M3 - Article

AN - SCOPUS:84906502928

SN - 2214-4420

VL - 2

SP - 150

EP - 151

JO - Urology Case Reports

JF - Urology Case Reports

IS - 5

ER -

Complete response to bicalutamide withdrawal prolonged for almost 2 years in patients with metastatic prostate cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this